Novavax Announces Proposed Public Offering of Common Stock
April 11 2018 - 4:01PM
Novavax, Inc. (Nasdaq:NVAX), a clinical-stage biotechnology company
committed to delivering novel products to prevent infectious
diseases, today announced that it intends to offer to sell, subject
to market and other conditions, shares of its common stock in an
underwritten public offering. As part of this offering Novavax
intends to grant the underwriters a 30-day option to purchase
additional shares of its common stock equal to up to 15% of the
number of shares of common stock offered pursuant to the
underwritten public offering.
Citigroup and Piper Jaffray & Co. are acting
as joint book-running managers of the offering.
All shares being offered are to be sold by
Novavax. Net proceeds from the offering are to be used for general
corporate purposes, including but not limited to working capital,
capital expenditures, research and development expenditures related
to clinical and preclinical vaccine candidates, as well as
acquisitions and other strategic purposes.
The securities described above are being offered
by Novavax pursuant to its registration statement on Form S-3
previously filed and declared effective by the Securities and
Exchange Commission (SEC). This press release does not constitute
an offer to sell or a solicitation of an offer to buy the
securities in the offering, nor shall there be any sale of these
securities in any jurisdiction in which an offer, solicitation or
sale would be unlawful prior to registration or qualification under
the securities laws of such jurisdiction. The offering may be made
only by means of the preliminary prospectus supplement and the
prospectus relating to the proposed offering, copies of which may
be obtained, when available, from Citigroup and Piper Jaffray &
Co., Attention: Citigroup, c/o Broadridge Financial Solutions, 1155
Long Island Avenue, Edgewood, NY 11717, by telephone at (800)
831-9146; or Piper Jaffray & Co., Attention: Prospectus
Department, 800 Nicollet Mall, J12S03, Minneapolis, MN 55402, by
telephone at (800) 747-3924 or by email at prospectus@pjc.com.
About Novavax
Novavax, Inc. (Nasdaq:NVAX) is a clinical-stage
biotechnology company committed to delivering novel products to
prevent infectious diseases. Its RSV and influenza nanoparticle
vaccine candidates are Novavax’ most advanced clinical programs and
are at the forefront of Novavax’ efforts to improve global
health.
Forward-Looking Statements
Statements contained in this press release,
including those relating to the sale of common stock, and those
statements using words such as “expects” and “intends” are
forward-looking statements that involve a number of risks and
uncertainties that could cause actual results to differ materially
from those in the forward-looking statements. These risks and
uncertainties include, but are not limited to: our ability to
successfully complete the offering on terms and conditions
satisfactory to us; the possible adverse impact on the market price
of our shares of common stock due to the dilutive effect of the
securities to be sold in the offering; our planned use of the
proceeds from this offering; capital market risks; our ability to
raise additional capital when needed; and other risk factors
identified in Part I, Item 1A “Risk Factors,” of the Novavax Annual
Report on Form 10-K for the year ended December 31, 2017 as filed
with the Securities and Exchange Commission (SEC) and in other
reports filed from time to time with the SEC, including our
Quarterly Reports on Form 10-Q and Current Reports on Form 8-K,
which are all available at www.sec.gov. We caution investors not to
place considerable reliance on the forward-looking statements
contained in this press release. The forward-looking statements in
this press release speak only as of the date of this document, and
we undertake no obligation to update or revise any of the
statements. Our business is subject to substantial risks and
uncertainties, including those referenced above. Investors,
potential investors, and others should give careful consideration
to these risks and uncertainties.
Contact:
Investors:Erika TrahanSenior Manager, Investor & Public
Relationsir@novavax.com240-268-2000
Westwicke PartnersJohn
WoolfordJohn.woolford@westwicke.com443-213-0506
Media:Sam BrownMike Beyermikebeyer@sambrown.com312-961-2502
Novavax (NASDAQ:NVAX)
Historical Stock Chart
From Sep 2024 to Oct 2024
Novavax (NASDAQ:NVAX)
Historical Stock Chart
From Oct 2023 to Oct 2024